DOLAPO GBADEHAN: Open Payments
NPI 1477252047 · ATLANTA, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$409 in 20 payments from 13 companies in 2025. Trend: 2023 $0 · 2024 $529 · 2025 $409
Food & beverage: $409
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 3 | $87 |
| Exact Sciences Corporation | 4 | $69 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $38 |
| AstraZeneca Pharmaceuticals LP | 2 | $36 |
| Novo Nordisk Inc | 1 | $24 |
| Dynavax Technologies Corporation | 1 | $23 |
| SANOFI-AVENTIS U.S. LLC | 1 | $21 |
| Lilly USA, LLC | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $20 |
| Dexcom, Inc. | 1 | $20 |
Products named: Veozah, Cologuard Collection Kit, Kerendia, JARDIANCE, Ozempic, Heplisav-B, TZIELD, OPSUMIT.
Industry payments across GA — which companies pay providers there.
